104 related articles for article (PubMed ID: 32164113)
21. CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.
Müller F; Taubmann J; Bucci L; Wilhelm A; Bergmann C; Völkl S; Aigner M; Rothe T; Minopoulou I; Tur C; Knitza J; Kharboutli S; Kretschmann S; Vasova I; Spoerl S; Reimann H; Munoz L; Gerlach RG; Schäfer S; Grieshaber-Bouyer R; Korganow AS; Farge-Bancel D; Mougiakakos D; Bozec A; Winkler T; Krönke G; Mackensen A; Schett G
N Engl J Med; 2024 Feb; 390(8):687-700. PubMed ID: 38381673
[TBL] [Abstract][Full Text] [Related]
22. Jain MD, Ziccheddu B, Coughlin CA, et al. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood. 2022;140(5):491-503.
Blood; 2023 Oct; 142(14):1255. PubMed ID: 37796516
[No Abstract] [Full Text] [Related]
23. Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity.
Di Staso R; Casadei B; Gentilini M; Guadagnuolo S; Pellegrini C; Broccoli A; Gori D; Masetti R; Stefoni V; Bonifazi F; Zinzani PL; Argnani L
Ann Hematol; 2024 May; ():. PubMed ID: 38695872
[TBL] [Abstract][Full Text] [Related]
24. Third-generation CD19.CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis.
Merkt W; Freitag M; Claus M; Kolb P; Falcone V; Röhrich M; Rodon L; Deicher F; Andreeva I; Tretter T; Tykocinski LO; Blank N; Watzl C; Schmitt A; Sauer T; Müller-Tidow C; Polke M; Heußel CP; Dreger P; Lorenz HM; Schmitt M
Ann Rheum Dis; 2024 Mar; 83(4):543-546. PubMed ID: 38135464
[No Abstract] [Full Text] [Related]
25. Remission after CAR T-cell therapy: Do lymphoma patients recover a normal life?
Perthus A; Colin F; Charton E; Anota A; Lhomme F; Manson G; De Guibert S; Daufresne P; Bellec A; Le Bars L; De Barros S; Ysebaert L; Merceur M; Cogné M; Lamy De La Chapelle T; Houot R; Moignet A
Hemasphere; 2024 May; 8(5):e72. PubMed ID: 38803454
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcomes of relapsed/refractory double-hit lymphoma (r/r DHL) treated with CD19/22 CAR T-cell cocktail therapy.
Wei J; Mao Z; Wang N; Huang L; Cao Y; Sun W; Long X; Tan J; Li C; Xiao Y; Gu C; Zhang S; Zhang Y; Zhang T; Zhou J; Huang L
Clin Transl Med; 2020 Sep; 10(5):e176. PubMed ID: 32997409
[No Abstract] [Full Text] [Related]
27. Efficacy of CAR T-Cell Therapy is Not Impaired by Previous Bispecific Antibody Treatment in Large B-Cell Lymphoma.
Crochet G; Iacoboni G; Couturier A; Bachy E; Iraola-Truchuelo J; Gastinne T; Cartron G; Fradon T; Lesne B; Kwon M; Gounot R; Martínez-Cibrian N; Castilla-Llorente C; Abrisqueta P; Guerreiro M; Sarkozy C; Aspa-Cilleruelo JM; Camus V; Guidez S; Chauchet A; Deconinck E; Bouabdallah K; Bosch F; Barba P; Morschhauser F; Houot R
Blood; 2024 Apr; ():. PubMed ID: 38657242
[TBL] [Abstract][Full Text] [Related]
28. Radiotherapy as a bridging strategy for patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy.
Ababneh HS; Ng AK; Frigault MJ; Jacobson CA; Patel CG
Am J Hematol; 2024 Jun; ():. PubMed ID: 38860643
[No Abstract] [Full Text] [Related]
29. Highlight of 2023: CAR T cells driving precision therapy for autoimmune disease.
Lee AY; Reed JH
Immunol Cell Biol; 2024 May; ():. PubMed ID: 38693765
[TBL] [Abstract][Full Text] [Related]
30. Correction: Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.
Ormhøj M; Scarfò I; Cabral ML; Bailey SR; Lorrey SJ; Bouffard AA; Castano AP; Larson RC; Riley LS; Schmidts A; Choi BD; Andersen RS; Cédile O; Nyvold CG; Christensen JH; Gjerstorff MF; Ditzel HJ; Weinstock DM; Barington T; Frigault MJ; Maus MV
Clin Cancer Res; 2024 May; 30(10):2286. PubMed ID: 38745479
[No Abstract] [Full Text] [Related]
31. Cluster of differentiation 19 chimeric antigen receptor T-cell therapy in pediatric acute lymphoblastic leukemia.
Fu Z; Zhou J; Chen R; Jin Y; Ni T; Qian L; Xiao C
Oncol Lett; 2020 Oct; 20(4):36. PubMed ID: 32802160
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
33. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
Zhu Y; Tan Y; Ou R; Zhong Q; Zheng L; Du Y; Zhang Q; Huang J
Eur J Haematol; 2016 Apr; 96(4):389-96. PubMed ID: 26115358
[TBL] [Abstract][Full Text] [Related]
34. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
Du J; Zhang Y
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815
[TBL] [Abstract][Full Text] [Related]
35. [Analysis on poor efficacy factors in the treatment of recurrent/refractory B-cell lymphoma with CD19 CAR-T cells].
Xiao X; Yuan T; Meng JX; Jiang YY; Cao YQ; Li Q; Sun R; Zhao MF
Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(8):593-598. PubMed ID: 32164113
[No Abstract] [Full Text] [Related]
36. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
[No Abstract] [Full Text] [Related]
37. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
